MARLBOROUGH, Mass.,
Nov. 25, 2016 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) will highlight its portfolio of
innovative, award-winning breast cancer screening and
interventional products, including the new Affirm™ prone breast
biopsy system, at the 102nd Scientific Assembly and
Annual Meeeting of the Radiological Society of North America (RSNA) at McCormick Place in
Chicago from Nov. 27 to Dec. 2. With more than 60 papers,
presentations and courses focusing on 3D MAMMOGRAPHY™ exams,
Hologic's product and educational offerings at RSNA underscore the
continued importance of tomosynthesis technologies, while driving
innovation and education in breast health.
"It's always an honor to spend the week with many of the world's
most respected radiologists, but this RSNA, we are particularly
excited to allow hands-on experiences with our Affirm prone breast
biopsy system, our latest advancement in breast biopsy technology,"
said Pete Valenti, Hologic's
Division President, Breast and Skeletal Health Solutions. "As the
only manufacturer with a core focus on innovating and advancing
breast health, we are committed to introducing new products, like
the Affirm prone system, that offer unique patient and user
benefits and address workflow challenges, enhancing the
overall healthcare experience."
Available for demonstrations for the first time since receiving
FDA clearance earlier this year, the Affirm prone breast biopsy
system — the first dedicated prone biopsy system that is upgradable
to allow for 3D™ imaging-guided breast
biopsies — marks the first significant step forward in prone biopsy
technology since systems were first introduced more than 20 years
ago. The Affirm prone system, which was recently recognized by Aunt
Minnie as a finalist in its 2016 Best New Radiology Device
category, provides clinicians with added confidence through
superior imaging, 3D™ biopsy capability,
faster and easier workflow, and seamless, 360-degree access to the
breast.1 Early clinical and patient feedback has been
positive, with more than 95 percent of patients indicating in a
recent post-procedure survey that the biopsy experience was faster,
more comfortable and less painful than expected.2
Hologic also has continued to expand its
Affirm™ upright biopsy system with the
launch of the Affirm™ lateral arm biopsy
accessory, which will be available for demonstrations at RSNA for
the first time since its launch. This versatile, easy-to-use device
enables needle access parallel to the detector, allowing physicians
to target challenging lesions confidently and successfully biopsy
thinly compressed breasts.
Hologic, which was ranked this month as the highest-scoring
imaging equipment manufacturer for mammography in the 2016 Best in
KLAS: Medical Equipment report for the seventh consecutive year,
will showcase its complete line of screening and interventional
products at RSNA, including several key products highlighted in
clinical studies this year:
- The Genius™ 3D MAMMOGRAPHY™ exam, only
available on the Selenia®
Dimensions® system, is Hologic's breast
tomosynthesis exam, which has been shown to reduce recall rates,
increase invasive cancer detection and find invasive cancer earlier
through a significant body of literature published this year in
major research journals, including JAMA, JAMA
Oncology, and The Breast. 3,4,5
- Low Dose 3D MAMMOGRAHY™ exams with C-View™ Software
result in less time under compression, increasing patient comfort
at a lower radiation dose. Recent clinical studies, published this
year in Lancet Oncology and Radiology, have shown
that screening exams using C-View 2D images result in comparable
clinical performance to traditional 3D MAMMOGRAPHY™
exams.6,7
- I-View™ Software for Contrast-Enhanced 2D Digital
Mammography (CEDM) exams are performed following a mammogram
and/or ultrasound, as an alternative to breast MRI, to learn more
about a suspicious area and determine surgical therapy for breast
cancer patients. Recent literature published on CEDM in the
Annals of Surgical Oncology illustrates the promising
potential for facilities' bottom lines, as well as the patient
experience, by using I-View software. 8
Additionally, Hologic will offer several 3D MAMMOGRAPHY™
exam-related educational events at RSNA:
- RSNA Satellite Symposium, "Addressing the Clinical Need for
3DTM Breast Biopsy Technologies: Prone and Upright
Solutions," on Sunday, November
27 from 1:30 p.m. –
3:00 p.m.
- 60-Minute Hands-On Workshop, "3D™ Image Guided Prone Breast
Biopsy: A Seasoned Perspective," on Sunday, November 27 from 10:30 a.m. – 11:30
a.m. and Monday, November 28
from 12:15 p.m. – 1:15 p.m.
- Advanced 75-Minute Hands-On Workshop, "Optimizing
Tomosynthesis: Strategies for Improving Mammographic Outcomes,"
on Monday, November 28 from
3:30 p.m. – 4:45 p.m. and Tuesday,
November 29 from 12:00 p.m. –
1:15 p.m.
RSNA is an international society of radiologists, medical
physicists and other medical professionals with 55,000 members from
more than 140 countries. The RSNA Annual Meeting is expected to
attract more than 60,000 attendees.
For additional information on Hologic's Affirm prone biopsy
system or other solutions, visit Hologic's booth at RSNA, located
in the McCormick Place South Building – Level 3, Exhibit # 4111.
For each station visited in the Hologic booth, the Company will
donate $1 to Bright Pink, the only
national non-profit focused on the prevention and early detection
of breast and ovarian cancer in young women, as part of its
"Explore for Charity" program.
About Hologic
Hologic, Inc. is a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products. The Company's core business
units focus on diagnostics, breast health, GYN surgical, and
skeletal health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic, 3D, 3D Mammography, Affirm, C-View, Dimensions, Genius,
I-View, Selenia, and The Science of Sure and associated logos are
trademarks and/or registered trademarks of Hologic, Inc., and/or
its subsidiaries in the United
States and/or other countries.
Forward-looking Statement Disclaimer:
This news
release may contain forward-looking information that involves risks
and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated
in any particular manner with respect to an individual patient, as
the actual effect of the use of the products can only be determined
on a case-by-case basis. In addition, there can be no assurance
that these products will be commercially successful or achieve any
expected level of sales. Hologic expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such data or statements are based.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael Watts
858.410.8588
michael.watts@hologic.com
1 Compared to the MultiCare® Platinum
system
2 Data on file 2016. Hologic survey of 165 patients
post procedure at 3 hospitals.
3 Elizabeth Rafferty,
MD, Melissa Durand, MD, Emily Conant, MD, Debra
Somers Copit, MD, Sarah M.
Friedewald, MD, Donna M.
Plecha, MD, and Dave P.
Miller, MS. "Breast cancer screening using tomosynthesis and
digital mammography in dense and nondense breasts," JAMA.
2016;315(16):1784-1786.
4 Elizabeth S.
McDonald, MD, PhD; Andrew Oustimov, MPH; Susan P. Weinstein, MD; Marie B. Synnestvedt, PhD; Mitchell Schnall, MD, PhD, and Emily F. Conant, MD. Effectiveness of Digital
Breast Tomosynthesis Compared with Digital Mammography. JAMA
Oncol. 2016;2(6):1-7. Doi:10:10.1001/jamoncol. 2015.5536.
5 Hodgson R, Heywang-Kobrunner S, Harvey S, et al.
Systematic Review of 3D Mammography for Breast Cancer Screening.
The Breast. 2016;27:52-61 [epub ahead of print].
6 Bernardi D, Pellegrini M, Valentini M, et al.
"Breast cancer screening with tomosynthesis (3D mammography) with
acquired or synthetic 2D mammography compared with 2D mammography
alone (STORM-2): a population-based prospective study." The Lancet
Oncology. Epub 2016 June 23.
7 Zuckerman S, Conant E, Keller B, et al.
"Implementation of Synthesized Two-dimensional Mammography in a
Population-based Digital Breast Tomosynthesis Screening Program."
Radiology. 10.1148/radiol.2016160366
8 Ali-Mucheru M, Pockaj B, Patel B, et al.
"Contrast-Enhanced Digital Mammography in the Surgical Management
of Breast Cancer."Annals of Surgical Oncology. Epub 2016 September
15. DOI 10.1245/s10434-016-5567-7
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-to-showcase-award-winning-breast-screening-and-interventional-solutions-at-rsna-2016-300368384.html
SOURCE Hologic, Inc.